Mesa Laboratories (NASDAQ:MLAB) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research note issued on Tuesday.
According to Zacks, “MESA LABORATORIES, INC. designs, develops, acquires, manufactures and markets instruments and systems utilized in connection with industrial applications and hemodialysis therapy. “
Separately, TheStreet upgraded shares of Mesa Laboratories from a “c+” rating to a “b” rating in a research note on Monday, November 6th.
Mesa Laboratories (MLAB) traded up $0.82 during trading on Tuesday, reaching $133.66. 4,394 shares of the company’s stock traded hands, compared to its average volume of 14,478. The company has a current ratio of 2.86, a quick ratio of 1.97 and a debt-to-equity ratio of 0.48. Mesa Laboratories has a 52-week low of $113.57 and a 52-week high of $169.80. The company has a market cap of $502.10, a price-to-earnings ratio of 48.25 and a beta of 0.42.
Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings results on Monday, November 6th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.64 by ($0.04). Mesa Laboratories had a return on equity of 14.77% and a net margin of 11.48%. The firm had revenue of $22.95 million for the quarter, compared to the consensus estimate of $25.50 million. equities research analysts expect that Mesa Laboratories will post 2.47 EPS for the current fiscal year.
Several large investors have recently added to or reduced their stakes in MLAB. Conestoga Capital Advisors LLC increased its stake in shares of Mesa Laboratories by 5.8% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 373,227 shares of the medical instruments supplier’s stock valued at $55,730,000 after acquiring an additional 20,489 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of Mesa Laboratories by 11.8% in the 3rd quarter. Victory Capital Management Inc. now owns 147,468 shares of the medical instruments supplier’s stock valued at $22,020,000 after acquiring an additional 15,580 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Mesa Laboratories by 10.1% in the 2nd quarter. Vanguard Group Inc. now owns 145,161 shares of the medical instruments supplier’s stock valued at $20,804,000 after acquiring an additional 13,263 shares in the last quarter. Thomson Horstmann & Bryant Inc. increased its stake in shares of Mesa Laboratories by 14.5% in the 4th quarter. Thomson Horstmann & Bryant Inc. now owns 88,379 shares of the medical instruments supplier’s stock valued at $10,985,000 after acquiring an additional 11,164 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in shares of Mesa Laboratories in the 3rd quarter valued at $1,470,000. Institutional investors own 69.79% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Upgrades Mesa Laboratories (MLAB) to “Hold”” was originally published by Stock Observer and is the sole property of of Stock Observer. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.thestockobserver.com/2018/01/13/zacks-investment-research-upgrades-mesa-laboratories-mlab-to-hold.html.
About Mesa Laboratories
Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.